Related Experiment Video
Updated: Aug 6, 2026
12:40
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Raf kinases: oncogenesis and drug discovery
1Institut für Medizinische Strahlenkunde und Zellforschung, MSZ, Universität Würzburg, Würzburg, Germany.
International Journal of Cancer
|August 9, 2006
Summary
Raf kinase signaling, involving A-Raf, B-Raf, and C-Raf, plays a role in cell growth and cancer. Research focuses on B-RAF mutations and developing targeted anticancer therapies.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Raf kinases (A-Raf, B-Raf, C-Raf) are key regulators of cellular processes including growth, proliferation, and differentiation.
- Aberrant Raf kinase signaling is implicated in various human cancers.
- B-RAF mutations are frequently detected in diverse cancer types, highlighting its oncogenic potential.
Purpose of the Study:
- To review recent advancements in Raf kinase research concerning tumor formation.
- To provide an overview of current therapeutic strategies targeting aberrant Raf kinase signaling.
- To discuss the significance of B-RAF mutations and tumor antigens in cancer research.
Main Methods:
- Literature review of Raf kinase signaling pathways.
- Analysis of recent research outcomes on Raf kinases in tumor development.
- Survey of ongoing clinical trials for Raf-targeted therapies.
Main Results:
- B-RAF mutations are significant drivers in multiple human cancers.
- Wildtype and mutant B-RAF function as tumor antigens, particularly in melanoma.
- Clinical trials of Raf inhibitors like Sorafenib show promising results.
Conclusions:
- Targeting aberrant Raf kinase signaling is a promising strategy for cancer therapy.
- Continued research into Raf kinase pathways is crucial for developing effective anticancer treatments.
- Understanding B-RAF's role in tumorigenesis informs the development of novel therapeutic interventions.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:26Receptor Tyrosine Kinases
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
02:15M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...